RxDoctor Payments Data

David Young

Pediatric Hematology-Oncology · Bethesda, MDNPI 1578856670

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $300 of the $300 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for pediatric hematology-oncology clinicians in MD, where the typical reported total is $300.

$300in general payments, 2019–2025

Across 2 payments — averaging $150.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$300
$7,466,449in research payments, 2019–2025

Across 8 payments — averaging $933,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$7.5M

What the payments were for

  • Speaking & faculty fees$300100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$300

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300 in reported general payments places this provider in the 50th percentile of 52 pediatric hematology-oncology providers in Maryland.

See all pediatric hematology-oncology providers in Maryland

Other pediatric hematology-oncology in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →